SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zen_lunatic420 who wrote (24632)6/2/2014 6:55:28 PM
From: BMackie1 Recommendation

Recommended By
tradeinknow

   of 49402
 
Well said Zen. I have heard theTLT/MBX comparison before but still see TLT as a coin flip. Their laser division ("core business") is hopelessly unprofitable and they will have to raise millions for human clinical trials. The price they can raise at is a big risk IMO.

I am somewhat baffled by the market's lack of enthusiasm for MBX. Perhaps it is the lack of near-term catalysts on the horizon. Fair concern but still, a VIRUSMAX settlement could be reached well before the trial and a partner/buyer for Urokinase could surface any day. And last I talked with management, a LumiSort update will be due out in the fall (just a few months away).

I'm no bio-tech expert and couldn't tell you the odds of success of any drug/process out there. But with MBX, I don't have to - I'm getting the pipeline for free with little dilution risk to boot. I think MBX is a no-brainer.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News